A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer

被引：0
|
作者：
Cody J. Peer
Keith T. Schmidt
Jessica D. Kindrick
Joel R. Eisner
Victoria V. Brown
Edwina Baskin-Bey
Ravi Madan
William D. Figg
机构：
[1] National Cancer Institute,Clinical Pharmacology Program, CCR
[2] NIH,Genitourinary Malignancies Branch
[3] Innocrin Pharmaceuticals,undefined
[4] National Cancer Institute,undefined
[5] NIH,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2019年 / 84卷
关键词：
Seviteronel CYP17 lyase; Population pharmacokinetics; Prostate cancer;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：759 / 770
页数：11
相关论文
共 50 条
  • [1] A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
    Peer, Cody J.
    Schmidt, Keith T.
    Kindrick, Jessica D.
    Eisner, Joel R.
    Brown, Victoria V.
    Baskin-Bey, Edwina
    Madan, Ravi
    Figg, William D.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2019, 84 (04) : 759 - 770
  • [2] Phase I Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Men with Castration-Resistant Prostate Cancer
    Gupta, Shilpa
    Nordquist, Luke T.
    Fleming, Mark T.
    Berry, William R.
    Zhang, Jingsong
    Ervin, Sharon L.
    Eisner, Joel R.
    Baskin-Bey, Edwina S.
    Shore, Neal D.
    CLINICAL CANCER RESEARCH, 2018, 24 (21) : 5225 - 5232
  • [3] Targeting the androgen receptor with seviteronel, a CYP17 lyase and AR inhibitor, in triple negative breast cancer
    Reese, J. M.
    Babbs, B. L.
    Christenson, J. L.
    Spoelstra, N. S.
    Elias, A.
    Eisner, J. R.
    Baskin-Bey, E. S.
    Gertz, J.
    Richer, J. K.
    CANCER RESEARCH, 2019, 79 (04)
  • [4] Enzalutamide, an oral androgen receptor inhibitor for treatment of castration-resistant prostate cancer
    Sternberg, Cora N.
    FUTURE ONCOLOGY, 2019, 15 (13) : 1437 - 1457
  • [5] Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
    Michmerhuizen, Anna R.
    Chandler, Benjamin
    Olsen, Eric
    Wilder-Romans, Kari
    Moubadder, Leah
    Liu, Meilan
    Pesch, Andrea M.
    Zhang, Amanda
    Ritter, Cassandra
    Ward, S. Tanner
    Santola, Alyssa
    Nyati, Shyam
    Rae, James M.
    Hayes, Daniel
    Feng, Felix Y.
    Spratt, Daniel
    Wahl, Daniel
    Eisner, Joel
    Pierce, Lori J.
    Speers, Corey
    FRONTIERS IN ENDOCRINOLOGY, 2020, 11
  • [6] The discovery of BMS-737 as a potent, CYP17 lyase-selective inhibitor for the treatment of castration-resistant prostate cancer
    Darne, Chetan Padmakar
    Velaparthi, Upender
    Saulnier, Mark
    Frennesson, David
    Liu, Peiying
    Huang, Audris
    Tokarski, John
    Fura, Aberra
    Spires, Thomas
    Newitt, John
    Spires, Vanessa M.
    Obermeier, Mary T.
    Elzinga, Paul A.
    Gottardis, Marco M.
    Jayaraman, Lata
    Vite, Gregory D.
    Balog, Aaron
    BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2022, 75
  • [7] Targeting the androgen receptor in metastatic castration-resistant prostate cancer
    Aragon-Ching, Jeanny B.
    FUTURE ONCOLOGY, 2014, 10 (03) : 329 - 332
  • [8] Androgen receptor antagonist Treatment of metastatic castration-resistant prostate cancer Treatment of metastatic breast cancer
    Culig, Zoran
    DRUGS OF THE FUTURE, 2023, 48 (01) : 15 - 21
  • [9] CYP17 inhibitors improve the prognosis of metastatic castration-resistant prostate cancer patients: A meta-analysis of published trials
    Cao, Qi
    Bai, Peng
    Shi, Deyao
    Liao, Jiali
    Shi, Hangchuan
    Xing, Yifei
    Chen, Ke
    Zhang, Xiaoping
    JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, 2020, 16 (05) : 990 - 1001
  • [10] Androgen Receptor Directed Therapies in Castration-Resistant Metastatic Prostate Cancer
    Won Kim
    Charles J Ryan
    Current Treatment Options in Oncology, 2012, 13 : 189 - 200
12345